A number of research firms have changed their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):

  • 9/17/2016 – Vertex Pharmaceuticals was given a new $112.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 9/15/2016 – Vertex Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $105.00 to $109.00. They now have a “buy” rating on the stock.
  • 9/15/2016 – Vertex Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $113.00 price target on the stock.
  • 9/15/2016 – Vertex Pharmaceuticals had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $87.00 price target on the stock.
  • 9/15/2016 – Vertex Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $107.00 price target on the stock. They wrote, “This morning VRTX announced at a conference that Orkambi refills have lagged during 3Q, and we had the opportunity to meet with the company this morning to discuss commercial and clinical developments.””
  • 9/13/2016 – Vertex Pharmaceuticals is now covered by analysts at Raymond James Financial Inc.. They set a “market perform” rating on the stock.
  • 9/13/2016 – Vertex Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “market perform” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/16/2016 – Vertex Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $108.00 to $105.00. They now have a “buy” rating on the stock.
  • 8/16/2016 – Vertex Pharmaceuticals had its “hold” rating reaffirmed by analysts at Maxim Group.
  • 8/16/2016 – Vertex Pharmaceuticals had its “buy” rating reaffirmed by analysts at JMP Securities.
  • 8/16/2016 – Vertex Pharmaceuticals had its “buy” rating reaffirmed by analysts at RBC Capital Markets.
  • 8/16/2016 – Vertex Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $107.00 price target on the stock.
  • 8/16/2016 – Vertex Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $128.00 price target on the stock.
  • 8/15/2016 – Vertex Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $113.00 price target on the stock.
  • 7/31/2016 – Vertex Pharmaceuticals had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/31/2016 – Vertex Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $107.00 price target on the stock, up previously from $102.00. They wrote, “Guidance lower on fx pressure and delays closing Priory. ACHC’s 2Q:16 adjusted EPS (diluted) were in-line with expectations at $0.73, but a drop in the GBP to $1.30 from $1.45 in March ($0.11-$0.12 per share) and another two- to four-month delay in closing Priory ($0.08-$0.09) pushed full-year 2016 guidance down to $2.63-$2.65 from $2.81-$2.86. We still expect synergies to ultimately reach about $20 million, or $0.20 per share. Our new 2016 adjusted EPS estimate is $2.65 (vs. prior $2.90) and our initial 2017 estimate is $3.20. CMA issues appear resolved. CMA has indicated that ACHC’s offered undertakings or a modified version of them might satisfy the government’s anti- competition concerns, and while the CMA must approve the buyer, it appears that the process could be completed in two to four months. ACHC’s offer includes selling 19 of its UK healthcare facilities (750 beds) that account for $126 million, or 10%, of its pro forma U.K. revenue, and $39 million, or 13%, of its pro forma U.K. adjusted EBITDA.””
  • 7/28/2016 – Vertex Pharmaceuticals had its “hold” rating reaffirmed by analysts at Maxim Group.
  • 7/28/2016 – Vertex Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $113.00 price target on the stock, up previously from $104.00.
  • 7/28/2016 – Vertex Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $140.00 to $139.00. They now have an “overweight” rating on the stock.
  • 7/28/2016 – Vertex Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company. They wrote, “Celgene reported very solid Q2 financials, prompting management to raise 2016.””
  • 7/27/2016 – Vertex Pharmaceuticals was upgraded by analysts at TheStreet from a “sell” rating to a “hold” rating.

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) traded up 0.14% during midday trading on Wednesday, hitting $91.82. 1,934,059 shares of the stock were exchanged. The stock’s market cap is $22.75 billion. The stock’s 50-day moving average price is $97.52 and its 200 day moving average price is $89.51. Vertex Pharmaceuticals Inc. has a one year low of $75.90 and a one year high of $134.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.21 by $0.03. The business earned $431.61 million during the quarter, compared to analyst estimates of $428.08 million. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The company’s quarterly revenue was up 159.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) earnings per share. On average, analysts anticipate that Vertex Pharmaceuticals Inc. will post $1.00 earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/recent-research-analysts-ratings-changes-for-vertex-pharmaceuticals-vrtx.html

In related news, Director Joshua S. Boger sold 6,500 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $92.37, for a total value of $600,405.00. Following the completion of the sale, the director now owns 274,725 shares of the company’s stock, valued at $25,376,348.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joshua S. Boger sold 5,130 shares of the company’s stock in a transaction dated Wednesday, June 29th. The stock was sold at an average price of $84.82, for a total transaction of $435,126.60. Following the completion of the sale, the director now directly owns 273,355 shares of the company’s stock, valued at approximately $23,185,971.10. The disclosure for this sale can be found here. Insiders own 1.90% of the company’s stock.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.